文献速递泌尿生殖技术与安全SPECTCT

PSMA靶向放射性药物治疗[177Lu]Ludotadipep在转移性去势抵抗性前列腺癌患者中的I期研究剂量学分析

Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [177Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · Korean J Radiol · 2024-01-01

该I期研究评估了新型PSMA靶向治疗药物[177Lu]Ludotadipep在25例转移性去势抵抗性前列腺癌患者中的生物分布与剂量学,采用单次给药活性递增设计(1.85至5.55 GBq)。结果显示唾液腺、肾、红骨髓等正常器官的吸收剂量系数,肿瘤吸收剂量系数为10.43±7.77 Gy/GBq。结论认为在II期临床试验计划的3.7 GBq×6周期剂量下预期安全,肾脏和骨髓为关键器官,且肿瘤吸收剂量高。

要点

  • 肿瘤吸收剂量系数为10.43±7.77 Gy/GBq,明显高于正常器官。
  • 肾脏和红骨髓的吸收剂量系数分别为0.77±0.28和0.07±0.02 Gy/GBq,为关键器官。
  • II期试验计划剂量3.7 GBq×6周期,预期安全。

核心结论

  • [177Lu]Ludotadipep在II期临床试验计划的3.7 GBq×6周期剂量下预期安全,肾脏和骨髓为关键器官,且显示高肿瘤吸收剂量。

研究设计与样本

  • I期研究,采用活性递增设计,单次给药[177Lu]Ludotadipep(1.85、2.78、3.70、4.63和5.55 GBq)。
  • 纳入25例转移性去势抵抗性前列腺癌患者(中位年龄73岁,范围60-90岁)。
  • 通过全身扫描和腹部SPECT/CT图像(给药后2、24、48、72和168小时)估算唾液腺、肺、肝、肾和脾的活性。
  • 通过给药后3、10、30、60和180分钟以及24、48和72小时的血样计算红骨髓活性;使用IDAC-Dose 2.1进行器官和肿瘤吸收剂量计算。

诊断标准与关键数值

  • 正常器官吸收剂量系数(均值±标准差):唾液腺1.17±0.81 Gy/GBq,肺0.05±0.02 Gy/GBq,肝0.14±0.06 Gy/GBq,肾0.77±0.28 Gy/GBq,脾0.12±0.06 Gy/GBq,红骨髓0.07±0.02 Gy/GBq。
  • 肿瘤吸收剂量系数为10.43±7.77 Gy/GBq。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: 177Lutetium [Lu] Ludotadipep is a novel prostate-specific membrane antigen targeting therapeutic agent with an albumin motif added to increase uptake in the tumors. We assessed the biodistribution and dosimetry of [177Lu]Ludotadipep in patients with metastatic castration-resistant prostate cancer (mCRPC).

MATERIALS AND METHODS: Data from 25 patients (median age, 73 years; range, 60-90) with mCRPC from a phase I study with activity escalation design of single administration of [177Lu]Ludotadipep (1.85, 2.78, 3.70, 4.63, and 5.55 GBq) were assessed. Activity in the salivary glands, lungs, liver, kidneys, and spleen was estimated from whole-body scan and abdominal SPECT/CT images acquired at 2, 24, 48, 72, and 168 h after administration of [177Lu]Ludotadipep. Red marrow activity was calculated from blood samples obtained at 3, 10, 30, 60, and 180 min, and at 24, 48, and 72 h after administration. Organ- and tumor-based absorbed dose calculations were performed using IDAC-Dose 2.1.

RESULTS: Absorbed dose coefficient (mean ± standard deviation) of normal organs was 1.17 ± 0.81 Gy/GBq for salivary glands, 0.05 ± 0.02 Gy/GBq for lungs, 0.14 ± 0.06 Gy/GBq for liver, 0.77 ± 0.28 Gy/GBq for kidneys, 0.12 ± 0.06 Gy/GBq for spleen, and 0.07 ± 0.02 Gy/GBq for red marrow. The absorbed dose coefficient of the tumors was 10.43 ± 7.77 Gy/GBq.

CONCLUSION: [177Lu]Ludotadipep is expected to be safe at the dose of 3.7 GBq times 6 cycles planned for a phase II clinical trial with kidneys and bone marrow being the critical organs, and shows a high tumor absorbed dose.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Ha S, O JH, Park C, et al. Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [177Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer. Korean J Radiol. 2024. PMID: 38288897. doi:10.3348/kjr.2023.0656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。